SEHK:9926Biotechs
Gumokimab sNDA Acceptance for Ankylosing Spondylitis Could Be A Game Changer For Akeso (SEHK:9926)
Earlier this month, Akeso announced that China’s National Medical Products Administration accepted its supplemental New Drug Application for gumokimab (AK111), an anti‑IL‑17A antibody for active ankylosing spondylitis, supported by positive Phase III data.
This milestone highlights Akeso’s expanding non‑oncology portfolio and the potential for gumokimab to address a large ankylosing spondylitis patient population in China.
We’ll now examine how gumokimab’s sNDA acceptance, supported by...